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a B S T r a c T
Different strategies have been adopted for prevention of spontaneous preterm birth, including use of progestogens. So 
far, five randomized trials have been published evaluating the efficacy of progestogens in women with PPROM, in-
cluding a total of 425 participants. All the five trials enrolled pregnant women with singleton pregnancies randomized 
between 20 and 34 weeks of gestation. In four trials women were randomized to either weekly intramuscular 250 mg 
17α-hydroxyprogesterone-caproate or placebo, while Mirzaei et al. was a three arms trials in which women received 
weekly intramuscular 250 mg 17α-hydroxyprogesterone-caproate, or rectal progesterone 400 mg daily, or no treatment. 
In all the trials, latency antibiotics were used, and tocolysis was used permitted for first 48 hours at discretion of attend-
ing physician. Recently a meta-analysis including the five trials has been published. They found that when compared to 
placebo weekly intramuscular 250 mg 17α-hydroxyprogesterone-caproate did not alter the latency period to delivery in 
singleton gestations with PPROM. Additionally, there was no difference in gestational age at delivery between groups 
or in mode of delivery. No significant differences were reported in maternal or neonatal outcomes, with latency not sig-
nificantly altered in sensitivity analyses. So far, no trials have been published evaluating natural vaginal progesterone in 
women with PPROM.
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Preterm birth is defined as birth before 37 weeks of gestation.1 an estimated 15 million 
infants are born preterm every year, with short- 
and long-term complications in the survivors.
Preterm birth includes elective delivery for 
maternal or fetal indications, defined as iatro-
genic or medically indicated preterm birth, and 
spontaneous preterm birth, including either 
spontaneous onset of preterm labor or preterm 
premature rupture of membranes (PPROM).
about 25-30% of all spontaneous preterm de-
liveries follow PPROM, which is the most com-
monly cause of preterm birth in black women.1 
In women with PPROM, antibiotics have been 
shown to safely extend latency and decrease the 
risks of maternal and neonatal infection.2, 3
Progestagens, progestins, 
and natural progesterone
Different strategies have been adopted for pre-
vention of spontaneous preterm birth, includ-
ing use of progestogens.3-31 Progestogens, also 
known as progestagens or gestagens, are a class 
of steroid hormones that bind to and active the 
progesterone receptor. Progestogens include 
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natural progesterone, and progestins. Progestins 
are synthetic progestogens. Major examples of 
progestins include the 17α-hydroxyprogesterone 
derivative medroxyprogesterone acetate, and the 
19-nortestosterone derivative norethisterone. 
17α-hydroxyprogesterone-caproate is an ester of 
the 17α-hydroxyprogesterone.
Progestogen administration has been studied 
in different at-risk women. High quality evidence 
from randomized controlled trials supports use 
of vaginal natural progesterone in asymptomatic 
women with short transvaginal ultrasound cer-
vical length, in both singletons, at dose of 200 
mg daily,4 and twins, at dose of 400 mg daily,31 
while efficacy as maintenance tocolysis is actu-
ally still a subject of debate.8, 16 in women with 
prior spontaneous preterm birth progestogens 
given from about 16 weeks to 36 weeks of ges-
tation have been shown to be effective,4 with 
daily vaginal progesterone, either suppository 
or gel, better alternative to weekly intramuscular 
17α-hydroxyprogesterone-caproate.24
Preterm premature rupture 
of membranes
The membranes surrounding the amniotic cav-
ity are composed of the amnion and the chorion. 
Membranes normally rupture during labor. Pre-
mature rupture of membranes (PROM) refers to 
rupture of the fetal membranes prior to the onset 
of labor irrespective of gestational age. Preterm 
prelabor rupture of membranes (preterm PROM) 
is defined membrane rupture prior to 37 weeks 
gestational age. Its frequency is about 3% of 
pregnancies. PPROM is associated with several 
maternal and perinatal complications, including 
chorioamnionitis, operative delivery low birth 
weight, low APGAR score, respiratory distress 
syndrome, sepsis, necrotized enterocolitis, ad-
mission to NicU, intrauterine fetal death and 
neonatal death.32
A prior PPROM, vaginal infections, colla-
gen vascular disorders (such as ehlers-Danlos 
Syndrome, systemic lupus erythematosus), di-
rect abdominal trauma, preterm labor, cigarette 
smoking, illicit drugs (cocaine), anemia, low 
body mass index (BMI<20 kg/m2), nutritional 
deficiencies of copper and ascorbic acid, low 
socioeconomic status, are associated risk factors 
for PPROM.32 Uterine malformations may also 
be involved.
Progestagens and PPROM
So far, five randomized trials have been pub-
lished evaluating the efficacy of progestagens in 
women with PPROM, including a total of 425 
participants (Table I).33-37 All the five trials en-
rolled pregnant women with singleton pregnan-
cies randomized between 20 and 34 weeks of 
gestation. in four trials women were random-
Table I.— Trials evaluating progestogens for women with PPROM.
Briery,33 2011 combs,34 2011 combs,35 2015 Mirzaei,36 2014 langen,37 2018
Study location USa USa USa iran USa
Number of 
patients*
69 (33/36) 12 (4/8) 152 (74/78) 171 (57, 17-
OHPC; 57, rectal 
progesterone; 57 
control)
21 (10/11)
Progestogens 
treatment
17-OHPC 17-OHPC 17-OHPC 17-OHPC or rectal 
progesterone
17-OHPC
Dose, route, 
frequency
250mg IM, q week 250 mg IM, q week 250 mg IM, q week 17OHPC: 250 mg 
IM, q week; Rectal 
progesterone: 400 
mg daily
Not reported
control Placebo (castor oil) Placebo (castor oil) Placebo (castor oil) No treatment Vehicle without 
progestin component
included range 
gestational age 
at randomization 
(weeksdays)
200 - 300 230 - 316 230 - 306 240 - 340 240 - 320
*Total number (number in the progesterone group/number in the control group).
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